CD47-Targeted Antibody Polymer-Drug Conjugates: Immune Checkpoint Blockade and Targeted Cytotoxicity
Thursday, July 17, 2025
5:24 PM – 5:35 PM EDT
Introduction: CD47, a 'don't eat me' signal, enables cancer cell immune evasion through SIRPĪ±-mediated inhibition of macrophage phagocytosis [1]. Overexpressed in 90% of ovarian cancers but rare in normal tissues, CD47 (OA3) indicates poor prognosis [2]. We developed an N-(2-hydroxypropyl)methacrylamide (HPMA) polymer-based CD47 targeted antibody polymer-drug conjugate (U6244-092) to restore macrophage function and deliver paclitaxel (PTX), which enhances CD47 expression. U6244-092 offers dual benefits of immune activation and targeted cytotoxicity in ovarian cancer models.
Learning Objectives:
At the completion of this activity, participants will know
Understand the design of the antibody polymer-drug conjugates (pADC).
Discover the potential of dual-function pADC targeting immune checkpoints.
